Search | IOVS | ARVO Journals

Showing 1 – 20 of 101

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina March 2021

Evidence for Structural and Functional Damage of the Inner Retina in Diabetes With No Diabetic Retinopathy

PDF

Giovanni Montesano; Giovanni Ometto; Bethany E. Higgins; Radha Das; Katie W. Graham; Usha Chakravarthy; Bernadette McGuiness; Ian S. Young; Frank Kee; David M. Wright; David P. Crabb; Ruth E. Hogg
TAGS: diabetes mellitus, diabetes mellitus, type 2, diabetic retinopathy, retina
Invest. Ophthalmol. Vis. Sci.. 2021; 62(3):35. doi: https://doi.org/10.1167/iovs.62.3.35

Retina March 2021

Choroidal and Retinal Changes After Systemic Adrenaline and Photodynamic Therapy in Non-Human Primates

PDF

Kai Xiong Cheong; Veluchamy Amutha Barathi; Kelvin Yi Chong Teo; Usha Chakravarthy; Sai Bo Bo Tun; Joanna Marie Busoy; Candice Ee Hua Ho; Rupesh Agrawal; Kanji Takahashi; Chui Ming Gemmy Cheung
TAGS: epinephrine, photochemotherapy, primates
Invest. Ophthalmol. Vis. Sci.. 2021; 62(3):25. doi: https://doi.org/10.1167/iovs.62.3.25

Articles December 2020

Structure–Function Analysis in Macular Drusen With Mesopic and Scotopic Microperimetry

PDF

Giovanni Montesano; Giovanni Ometto; Bethany E. Higgins; Costanza Iester; Konstantinos Balaskas; Adnan Tufail; Usha Chakravarthy; Ruth E. Hogg; David P. Crabb

Trans. Vis. Sci. Tech.. 2020; 9(13):43. doi: https://doi.org/10.1167/tvst.9.13.43

ARVO Annual Meeting Abstract June 2020

Fibrosis and HRM changes in treated neovascular age-related macular degeneration: findings from multimodal imaging of the IVAN clinical trial

Luping Wang; Alyson Muldrew; Barney Reeves; Rebecca Nicole Evans; Alexandra Miere; Eric H Souied; Frank G Holz; Tim U Krohne; Tunde Peto; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2639. doi:

ARVO Annual Meeting Abstract June 2020

Real world outcomes for aflibercept in diabetic macula edema

Haralabos Eleftheriadis; Irene Mary Stratton; James S Talks; Peter Henry Scanlon; Shahram Kashani; Andrew J Lotery; Clare Bailey; Raj Mukherjee; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3290. doi:

ARVO Annual Meeting Abstract June 2020

Structure-Function Model for Intermediate Age-Related Macular Degeneration Microperimetry Data

Bethany Elora Higgins; Giovanni Montesano; Konstantinos Balaskas; Timos Naskas; Frank Kee; Usha Chakravarthy; Ruth E Hogg; David P. Crabb

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3241. doi:

ARVO Annual Meeting Abstract June 2020

Real-life long-term outcomes for patients treated with the 0.19 mg fluocinolone acetonide (FAc; ILUVIEN) intravitreal implant for DME: Three-year follow-up from the RegIstry Safety Study (IRISS) .

Ramin Khoramnia; Frank H J Koch; Usha Chakravarthy; Simon R Taylor; Joao Paulo Castro de Sousa; Clare Bailey

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4862. doi:

ARVO Annual Meeting Abstract June 2020

Sustained Vessel Stabilization Through Targeting Angiopoietin-2 (Ang-2) With Faricimab, a Bispecific Antibody Neutralizing Both Ang-2 and Vascular Endothelial Growth Factor A (VEGF-A)

Usha Chakravarthy; Richard Foxton; Sabine Uhles; Nadine Cole; Franco Revelant; Jayashree Sahni; Hugh Lin; Stefan Scheidl; Christoph Ullmer; Sascha Fauser

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):5126. doi:

Articles September 2019

Properties of the Impact of Vision Impairment and Night Vision Questionnaires Among People With Intermediate Age-Related Macular Degeneration

PDF

Myra B. McGuinness; Robert P. Finger; Zhichao Wu; Chi D. Luu; Fred K. Chen; Jenifer J. Arnold; Usha Chakravarthy; Wilson J. Heriot; Jim Runciman; Robyn H. Guymer; for the LEAD Study Group
TAGS: age-related macular degeneration, dark adaptation, questionnaires, vision, visual impairment, lead
Trans. Vis. Sci. Tech.. 2019; 8(5):3. doi: https://doi.org/10.1167/tvst.8.5.3

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2019

Real-world outcomes from the 3-year European ILUVIEN (0.19 mg fluocinolone acetonide implant) RegIstry Safety Study (IRISS)

Frank HJ Koch; Usha Chakravarthy; Ramin Khoramnia; Simon Taylor; Clare Bailey; João Sousa

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2622. doi:

ARVO Annual Meeting Abstract July 2019

Earlier intervention is associated with improved visual outcomes in patients with persistent or recurrent diabetic edema - Clinical insights from the ILUVIEN (fluocinolone acetonide) Registry Safety Study (IRISS)

Panos Vouzounis; Simon Taylor; Usha Chakravarthy; Clare Bailey; Frank HJ Koch; João Sousa

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2630. doi:

ARVO Annual Meeting Abstract July 2019

Aflibercept in the real world – are the visual outcomes worse in patients with diabetic macular edema who have had a cataract operation?

Irene Mary Stratton; Peter Henry Scanlon; James S Talks; Usha Chakravarthy; Raj Mukherjee; Faruque Ghanchi; Sajjad Mahmood; Andrew Lotery

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2637. doi:

ARVO Annual Meeting Abstract July 2019

The Carbon Footprint of Fluorescein Angiography compared to OCT Angiography

Rhianon Reynolds; Daniel Morris; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3050. doi:

ARVO Annual Meeting Abstract July 2019

The associations between the original randomized allocations and neovascular lesion morphology with low luminance acuity at the extended follow up visit in the IVAN clinical trial.

Alexander Foss; Barney Reeves; Rebecca Nicole Evans; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1177. doi:

ARVO Annual Meeting Abstract July 2019

Long-term clinical management of neovascular AMD and visual acuity outcome in IVAN trial participants

Barney Reeves; Rebecca Evans; Simon P Harding; Andrew Lotery; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1214. doi:

ARVO Annual Meeting Abstract July 2019

Can visual function tests act as early functional biomarkers of Diabetic Retinopathy prior to clinical features?

Radha Das; Jennifer Perais; Katie Graham; Klainti Timos Naska; Sophia Halliday; Nicola B Quinn; Usha Chakravarthy; Ruth Hogg

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5317. doi:

ARVO Annual Meeting Abstract July 2019

Retinal morphology and risk factors for the development of macular atrophy during extended follow up in the IVAN trial

Usha Chakravarthy; Tunde Peto; Rebecca Evans; Simon P Harding; Barney Reeves

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4223. doi:

ARVO Annual Meeting Abstract July 2019

Prevalence of Age-related macular degeneration using multi-modal retinal imaging in a population based aging cohort: the NICOLA Study

Ruth Esther Hogg; Nicola B Quinn; Tunde Peto; DAVID WRIGHT; Bernadette McGuinness; Ian Young; Frank Kee; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):63. doi:

ARVO Annual Meeting Abstract July 2019

Fequency of intra- and extralesional macular atrophy in the IVAN Follow-up trial

Tunde Peto; Rebecca Evans; Barney Reeves; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):84. doi:

ARVO Annual Meeting Abstract July 2019

Treatment response based on topography of retinal neovascularization in proliferative diabetic retinopathy

Sandra Halim; Amy A Kirkwood; Tunde Peto; Usha Chakravarthy; Jayashree Ramu; Philip G Hykin; Sobha Sivaprasad

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6555. doi:

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Evidence for Structural and Functional Damage of the Inner Retina in Diabetes With No Diabetic Retinopathy

Choroidal and Retinal Changes After Systemic Adrenaline and Photodynamic Therapy in Non-Human Primates

Structure–Function Analysis in Macular Drusen With Mesopic and Scotopic Microperimetry

Fibrosis and HRM changes in treated neovascular age-related macular degeneration: findings from multimodal imaging of the IVAN clinical trial

Real world outcomes for aflibercept in diabetic macula edema

Structure-Function Model for Intermediate Age-Related Macular Degeneration Microperimetry Data

Real-life long-term outcomes for patients treated with the 0.19 mg fluocinolone acetonide (FAc; ILUVIEN) intravitreal implant for DME: Three-year follow-up from the RegIstry Safety Study (IRISS) .

Sustained Vessel Stabilization Through Targeting Angiopoietin-2 (Ang-2) With Faricimab, a Bispecific Antibody Neutralizing Both Ang-2 and Vascular Endothelial Growth Factor A (VEGF-A)

Properties of the Impact of Vision Impairment and Night Vision Questionnaires Among People With Intermediate Age-Related Macular Degeneration

Real-world outcomes from the 3-year European ILUVIEN (0.19 mg fluocinolone acetonide implant) RegIstry Safety Study (IRISS)

Earlier intervention is associated with improved visual outcomes in patients with persistent or recurrent diabetic edema - Clinical insights from the ILUVIEN (fluocinolone acetonide) Registry Safety Study (IRISS)

Aflibercept in the real world – are the visual outcomes worse in patients with diabetic macular edema who have had a cataract operation?

The Carbon Footprint of Fluorescein Angiography compared to OCT Angiography

The associations between the original randomized allocations and neovascular lesion morphology with low luminance acuity at the extended follow up visit in the IVAN clinical trial.

Long-term clinical management of neovascular AMD and visual acuity outcome in IVAN trial participants

Can visual function tests act as early functional biomarkers of Diabetic Retinopathy prior to clinical features?

Retinal morphology and risk factors for the development of macular atrophy during extended follow up in the IVAN trial

Prevalence of Age-related macular degeneration using multi-modal retinal imaging in a population based aging cohort: the NICOLA Study

Fequency of intra- and extralesional macular atrophy in the IVAN Follow-up trial

Treatment response based on topography of retinal neovascularization in proliferative diabetic retinopathy

To View More...

You must be signed into an individual account to use this feature.